Does Semaglutide Cause Hair Loss? Ozempic vs Wegovy (2026)

Yes — semaglutide can cause hair loss, and the FDA-approved labels for Wegovy, Ozempic and Rybelsus all mention it, but how much you can know about your own odds depends on which product you take. Only the Wegovy label prints a measured rate (3.3% of adults on 2.4 mg versus 1% on placebo), and it ties that shedding to weight reduction ^[1]; the Ozempic injection label and the shared Rybelsus/Ozempic tablet label list alopecia only among postmarketing reports with no frequency ^[2][3], and compounded semaglutide has no FDA label to consult at all ^[4]. This page lines the four up side by side so you can see what each source actually establishes — and where the gaps are.

One molecule, five products: what each label tells you

Two details in that table are easy to miss. First, the oral form now comes under two brand names: the current tablet label covers both Rybelsus and a newer product sold as Ozempic tablets, and it states the two are not interchangeable milligram for milligram ^[3]. If you see “Ozempic” on a pill bottle, the label to read is the tablet label, not the injection label. Second, Wegovy itself now exists as a daily tablet, and its label gives a body-weight result but folds the tablet's side-effect profile into the injection data instead of printing a separate hair-loss number ^[1].

Wegovy: the only measured semaglutide rate

The Wegovy figure comes from a pooled analysis of three placebo-controlled weight trials covering 2,116 adults on 2.4 mg for up to 68 weeks; 71% of those participants were women ^[1]. Within that pool, hair loss appeared in 3.3% of people on the drug and 1% on placebo. The label adds one sentence that matters for interpretation: hair-loss reactions in Wegovy-treated patients “were associated with weight reduction” ^[1]. In plain terms, roughly two extra people in every hundred noticed shedding they would not have had on placebo, and the drug's maker attributes it to the weight coming off.

The higher 7.2 mg dose makes the same point from a different angle. In those trials, hair loss rose to 5.8%, against 3.3% on 2.4 mg and 1.0% on placebo, while average weight loss also rose (−18.8% versus −15.5% on 2.4 mg in the obesity study) ^[1]. In the 7.2 mg group, five hair-loss events led to a dose reduction, one to a temporary pause and one to stopping treatment for good ^[1]. Teens had a similar signal: 4% on 2.4 mg versus none on placebo ^[1]. The sex split is striking at every dose — at 7.2 mg, 8.4% of women versus 0.2% of men — so women should expect the label number to understate their personal odds. For the full Wegovy breakdown, see Wegovy and hair loss.

Ozempic and Rybelsus: listed, but not counted

Both diabetes labels mention alopecia in exactly one place: Section 6.2, the list of reactions “reported during post-approval use of semaglutide” ^[2][3]. The labels explain what that category means — reports arrive voluntarily from a population of unknown size, so it is not possible to reliably estimate how often they happen or to prove the drug caused them ^[2]. Alopecia does not appear in either label's clinical-trial adverse-reaction tables.

That absence is not proof the risk is zero. A plausible reading is that diabetes doses tend to produce smaller weight losses than the obesity doses do. The Wegovy label itself hints at this: in its trial of adults with type 2 diabetes, the same 2.4 mg dose produced a −9.6% average loss, versus −14.9% in the trial without diabetes ^[1]. Less weight lost, more slowly, is a weaker trigger for shedding. Observational data suggest the risk in diabetes is real but small: a 2026 BMJ target-trial emulation of adults with type 2 diabetes found that starting any GLP-1 receptor agonist was linked to a higher rate of diagnosed alopecia than starting an SGLT-2 inhibitor (hazard ratio 1.37) or a DPP-4 inhibitor (1.68), the signal was confined to non-scarring hair loss, and the authors stressed that the absolute risk is low ^[6]. That study covered the drug class, not semaglutide alone. More on the injection specifically: Ozempic and hair loss.

Compounded semaglutide: there is no number to look up

Compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are sold ^[4]. There is no prescribing information, no adverse-reaction table and no hair-loss rate. The tempting shortcut is to assume a compounded vial behaves like Wegovy and carries Wegovy's 3.3%. FDA's own warnings explain why that assumption is shaky:

• The ingredient may not be the same. FDA says some compounded products use salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the one in the approved drugs, and the agency has no information on whether they behave the same way ^[4].
• The dose may not be what you think. FDA has received adverse-event reports, some requiring hospitalization, tied to people measuring the wrong dose from compounded vials and to clinicians miscalculating doses, plus reports involving doses beyond what the approved label allows ^[4]. A higher-than-intended dose can mean faster weight loss, which is the very thing the Wegovy label links to shedding.
• The shortage rationale is gone. FDA states that semaglutide is not currently on its drug shortage list ^[5]; being on that list is one of the conditions under which outsourcing facilities may compound a drug from bulk ingredient.

So if you shed hair on compounded semaglutide, the honest answer is that no one can tell you whether your experience is typical, because no controlled data exist for that product. What you can do is tell your prescriber exactly what you were dispensed (ingredient name as printed, concentration and the volume you inject) so they can judge whether the dose matches what you intended. For the quality and equivalence questions in more depth, see compounded semaglutide bioequivalence.

Why the product matters less than the weight curve

The mechanism the evidence points to is telogen effluvium: a diffuse, non-scarring shed in which a stressor pushes many growing hairs into the resting phase at once, and they fall out together later. Crash dieting, low protein intake, iron deficiency and an underactive thyroid are all recognized triggers ^[9], and a large, fast drop in food intake can hit several of those at once. A 2026 meta-analysis of seventeen studies found GLP-1 drugs were tied to telogen effluvium and androgenetic (pattern) hair loss but not to alopecia areata, the patchy autoimmune type ^[8].

The randomized data line up with that picture. A 2026 meta-analysis limited to trials and prospective studies found hair loss was about three times as likely on a GLP-1 drug as on placebo (risk ratio 3.25), with an overall event rate of 3.9% ^[7] — close to Wegovy's labeled 3.3%. In global adverse-event reporting databases, semaglutide had the strongest hair-loss reporting signal of the GLP-1 drugs reviewed ^[8], but those reports track how widely a drug is used and talked about as much as true risk, so they cannot rank products. The class-wide comparison with tirzepatide lives on our GLP-1 hair loss hub.

What to do if you are shedding on semaglutide

1. Do not quit on your own. Talk to your prescriber first. In the Wegovy 7.2 mg trials, the usual response to troublesome shedding was lowering the dose, not stopping ^[1].
2. Ask for basic labs. Iron deficiency and hypothyroidism both cause the same diffuse shed ^[9], and both are fixable. Our iron and ferritin guide covers what to ask for.
3. Protect protein. Low protein intake is a recognized shedding trigger ^[9], and appetite suppression makes it easy to under-eat it.
4. Ask whether a slower pace makes sense. Because the Wegovy label ties hair loss to weight reduction and the rate climbs with the higher dose ^[1], staying longer on a lower dose is a reasonable question to raise.
5. If you use a compounded product, bring the vial label to your appointment and confirm the dose you are drawing up matches the prescription ^[4].
6. Treatment options exist if shedding persists; see minoxidil and finasteride on a GLP-1 for the evidence.